Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Orav

Showing results (421-430 of 431) with videos related to

Pageof 44
Sort By:
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
The Lancet. Oncology|September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
BMC Health Services Research|September 13, 2019
Design of MARQUIS2: study protocol for a mentored implementation study of an evidence-based toolkit to improve patient safety through medication reconciliationAmanda S Mixon, G Randy Smith, Meghan Mallouk, et al.
BMJ Quality & Safety|April 30, 2021
Effects of a refined evidence-based toolkit and mentored implementation on medication reconciliation at 18 hospitals: results of the MARQUIS2 studyJeffrey L Schnipper, Harry Reyes Nieva, Meghan Mallouk, et al.
BMJ Quality & Safety|March 22, 2023
What works in medication reconciliation: an on-treatment and site analysis of the MARQUIS2 studyJeffrey L Schnipper, Harry Reyes Nieva, Catherine Yoon, et al.
Contemporary Clinical Trials|August 10, 2021
Multilevel Follow-up of Cancer Screening (mFOCUS): Protocol for a multilevel intervention to improve the follow-up of abnormal cancer screening test resultsJennifer S Haas, Steven J Atlas, Adam Wright, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
Pageof 44

Showing results (421-430 of 431) with videos related to

Sort By:
Pageof 44
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
The Lancet. Oncology|September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
BMC Health Services Research|September 13, 2019
Design of MARQUIS2: study protocol for a mentored implementation study of an evidence-based toolkit to improve patient safety through medication reconciliationAmanda S Mixon, G Randy Smith, Meghan Mallouk, et al.
BMJ Quality & Safety|April 30, 2021
Effects of a refined evidence-based toolkit and mentored implementation on medication reconciliation at 18 hospitals: results of the MARQUIS2 studyJeffrey L Schnipper, Harry Reyes Nieva, Meghan Mallouk, et al.
BMJ Quality & Safety|March 22, 2023
What works in medication reconciliation: an on-treatment and site analysis of the MARQUIS2 studyJeffrey L Schnipper, Harry Reyes Nieva, Catherine Yoon, et al.
Contemporary Clinical Trials|August 10, 2021
Multilevel Follow-up of Cancer Screening (mFOCUS): Protocol for a multilevel intervention to improve the follow-up of abnormal cancer screening test resultsJennifer S Haas, Steven J Atlas, Adam Wright, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
Pageof 44